The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study.

BACKGROUND Differences in methods and data used in past studies have limited comparisons of the cost of illness of diabetes across countries. We estimate the full global economic burden of diabetes in adults aged 20-79 years in 2015, using a unified framework across all countries. Our objective was to highlight patterns of diabetes-associated costs as well as to identify the need for further research in low-income regions. METHODS Epidemiological and economic data for 184 countries were used to estimate the global economic burden of diabetes, regardless of diabetes type. Direct costs were derived using a top-down approach based on WHO general health expenditure figures and prevalence data from the 2015 International Diabetes Federation Diabetes Atlas. Indirect costs were assessed using a human-capital approach, including diabetes-associated morbidity and premature mortality. FINDINGS We estimate the global cost of diabetes for 2015 was US$1·31 trillion (95% CI 1·28-1·36) or 1·8% (95% CI 1·8-1·9) of global gross domestic product (GDP). Notably, indirect costs accounted for 34·7% (95% CI 34·7-35·0) of the total burden, although substantial variations existed both in the share and the composition of indirect costs across countries. North America was the most affected region relative to GDP and also the largest contributor to global absolute costs. However, on average, the economic burden as percentage of GDP was larger in middle-income countries than in high-income countries. INTERPRETATION Our results suggest a substantial global economic burden of diabetes. Although limited data were available for low-income and middle-income countries, our findings suggest that large diabetes-associated costs are not only a problem in high-income settings but also affect poorer world regions. FUNDING None.

[1]  A. Feigl,et al.  The Global Economic Burden of Noncommunicable Diseases , 2012 .

[2]  V. Mohan,et al.  Excess cost burden of diabetes in Southern India: a clinic-based, comparative cost-of-illness study , 2016, Global health, epidemiology and genomics.

[3]  E. Finkelstein,et al.  Comparing cost-of-illness estimates from alternative approaches: an application to diabetes. , 2009, Health services research.

[4]  Plamen Nikolov,et al.  Economic Costs of Diabetes in the U.S. in 2002 , 2003, Diabetes care.

[5]  Loukas Karabarbounis,et al.  The Global Decline of the Labor Share , 2013 .

[6]  M. Aagren,et al.  Cost of diabetes: comparison of disease-attributable and matched cohort cost estimation methods , 2010, Current medical research and opinion.

[7]  M. Anvari,et al.  The economic costs of diabetes: a population-based study in Tehran, Iran , 2009, Diabetologia.

[8]  J. Kirigia,et al.  Economic burden of diabetes mellitus in the WHO African region , 2009, BMC international health and human rights.

[9]  W. B. van den Hout,et al.  The value of productivity: human-capital versus friction-cost method , 2009, Annals of the rheumatic diseases.

[10]  H. Hauner,et al.  The cost burden of diabetes mellitus: the evidence from Germany—the CoDiM Study , 2006, Diabetologia.

[11]  Wenying Yang,et al.  Medical Care and Payment for Diabetes in China: Enormous Threat and Great Opportunity , 2012, PloS one.

[12]  S. Moebus,et al.  Direct costs in impaired glucose regulation: results from the population-based Heinz Nixdorf Recall study , 2016, BMJ Open Diabetes Research and Care.

[13]  M. M. Rahman,et al.  Worldwide trends in diabetes since 1980 : pooled analysis of 751 population-based measurement studies with over 4 . 4 million participants , 2016 .

[14]  Marc Suhrcke,et al.  The Economic Costs of Type 2 Diabetes: A Global Systematic Review , 2015, PharmacoEconomics.

[15]  M. Engelgau,et al.  Cost-of-Illness Studies in Diabetes Mellitus , 2012, PharmacoEconomics.

[16]  A. Barcelo,et al.  The cost of diabetes in Latin America and the Caribbean. , 2003, Bulletin of the World Health Organization.